First Bank & Trust Makes New Investment in Illumina, Inc. (NASDAQ:ILMN)

First Bank & Trust bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, Holdings Channel.com reports. The firm bought 1,256 shares of the life sciences company’s stock, valued at approximately $382,000.

A number of other large investors have also modified their holdings of ILMN. Nuveen Asset Management LLC boosted its position in Illumina by 67,829.8% during the second quarter. Nuveen Asset Management LLC now owns 2,260,705 shares of the life sciences company’s stock worth $832,279,000 after purchasing an additional 2,257,377 shares during the period. Thoroughbred Financial Services LLC boosted its position in Illumina by 38,516.8% during the second quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock worth $87,583,000 after purchasing an additional 873,560 shares during the period. Baillie Gifford & Co. boosted its position in shares of Illumina by 5.0% in the second quarter. Baillie Gifford & Co. now owns 16,775,175 shares of the life sciences company’s stock valued at $6,175,781,000 after acquiring an additional 799,884 shares during the period. Jennison Associates LLC boosted its position in shares of Illumina by 5.2% in the second quarter. Jennison Associates LLC now owns 5,976,219 shares of the life sciences company’s stock valued at $2,200,145,000 after acquiring an additional 296,541 shares during the period. Finally, Nikko Asset Management Americas Inc. boosted its position in shares of Illumina by 242.2% in the second quarter. Nikko Asset Management Americas Inc. now owns 416,303 shares of the life sciences company’s stock valued at $153,262,000 after acquiring an additional 294,643 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Shares of ILMN stock traded up $1.38 during trading hours on Thursday, hitting $311.05. 22,797 shares of the company’s stock were exchanged, compared to its average volume of 868,880. The company has a market capitalization of $45.62 billion, a PE ratio of 54.57, a PEG ratio of 3.09 and a beta of 1.07. Illumina, Inc. has a 12-month low of $263.30 and a 12-month high of $380.76. The business’s 50 day simple moving average is $293.87 and its 200-day simple moving average is $312.98. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.32 by $0.03. The firm had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The business’s revenue was up 1.0% compared to the same quarter last year. During the same period last year, the firm posted $1.43 earnings per share. Equities analysts anticipate that Illumina, Inc. will post 6.04 EPS for the current year.

A number of equities analysts have recently commented on ILMN shares. Bank of America lowered shares of Illumina from a “buy” rating to an “underperform” rating and set a $310.00 price objective for the company. in a research report on Friday, July 12th. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Wednesday. Deutsche Bank dropped their target price on shares of Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a research report on Friday, July 12th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, Credit Suisse Group reissued a “buy” rating and set a $340.00 price target on shares of Illumina in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $330.92.

In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $304.00, for a total transaction of $1,003,200.00. Following the transaction, the director now directly owns 269,316 shares of the company’s stock, valued at approximately $81,872,064. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 1,220 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $279.88, for a total transaction of $341,453.60. Following the transaction, the senior vice president now directly owns 5,386 shares in the company, valued at $1,507,433.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,099 shares of company stock worth $10,877,060. 0.38% of the stock is owned by insiders.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: What is a back-end load?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.